Anti-corticosteroids combined therapy for treatment of chronic central serous chorioretinopathy / Terapia combinada de anti-corticosteroides para o tratamento da coriorretinopatia serosa central

Abstract The therapeutic impact is described with the combined use of two medications with different anti-corticosteroid actions in the clinical resolution of a patient with chronic central serous chorioretinopathy.

Resumo Descrevemos nesse artigo o impacto terapêutico do uso combinado de duas medicações anti-corticosteroides com diferentes mecanismos de ação, na resolução clínica de um paciente com coriorretinopatia serosa central crônica.

Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis and cruris

The paper is intended to analyze and evaluate the specific curative effect and safety of 2% liranaftate ointment in treating patients with tinea pedis and tinea cruris. 1,100 cases of patients with tinea pedis and tinea corporis and cruris were selected as research objects and were divided into two groups according to the random number table method. They were treated with different methods: 550 cases of patients were treated with 2% liranaftate ointment for external use in the observation group and the rest 550 cases of patients were treated with 1% bifonazole cream in the control group. The treatment time was two weeks for patients with tinea corporis and cruris and four weeks for those with tinea pedis respectively. Meanwhile, the one-month follow-up visit was conducted among the patients to compare the curative effects of two groups. After the medication, the curative effectiveness rate was 87.65% [482/550] in the observation group, while that was 84.91% [467/550] in the control group. After the average follow-up visits of [15.5 +/- 2.4], the curative effectiveness rate 96.55% [531/550] in the observation group, while that was 91.45% [503/550] in the control group. Two groups of patients recovered well with a low incidence of adverse reactions in the treatment, and the overall curative effect was good with the inter-group difference at P>0.05, so it was without statistical significance. The curative effect of 2% liranaftate ointment is safe and obvious in treating tinea pedis and tinea corporis and cruris, so it is valuable for clinical popularization and application

Tiña negra (tinea nigra): comunicación de un caso alóctono en Chile / Tinea Nigra: a allochthonous case report in Chile

Tinea nigra is a superficial mycosis caused by Hortaea werneckii. It is an infrequent asymptomatic infection that affects mainly human palms and soles, and it is mostly seen in tropical countries. It has not been reported in Chile yet. The clinical presentation is generally a single macule, not symptomatic, of brown color in palms and soles. We report a case of a Chilean woman that developed brown macules on both soles after travel to the United States and Central America. The diagnosis of Tinea nigra was confirmed by direct microscopic examination and mycological culture. She had a good response to treatment with oral itraconazol.

La tiña negra (tinea nigra) es una micosis cutánea causada por Hortaea werneckii. Es poco frecuente, limitada a países tropicales o subtropicales. Hasta la presente publicación, esta micosis no había sido comunicada en Chile. La presentación clínica es generalmente una mácula única, asintomática, color café en palmas y plantas. Se presenta el caso de una mujer chilena, que después de varios viajes a E.U.A y Centroamérica, presentó manchas color café en ambas plantas. Se confirmó el diagnóstico de tiña negra con un examen microscópico directo y cultivo micológico. La paciente presentó una buena respuesta clínica luego del tratamiento con itraconazol por vía oral.

Balanites kernel oil for the treatment of dermatophytes: a clinical trial

In a previous in vitro study, we have shown that the kernel oil of fruits of the tree Balanites aegyptiaca referred to as Balanites kernel oil [BKO] is active against dermatophytes [i.e. superficial mycosis, ringworms, tineas [T. captitis, T. cercinata and T. pedis]. We report here our clinical trials with BKO. Trials were performed on patients presenting at Wad Medani Dermatology Teaching Hospital as well as primary school children in Elsoreeba Town [5 km south of Wad Medani]. Not all patients followed treatment till completely cured. Patients treated with BKO [half of the total] achieved complete cure in 3-5 weeks, on average, while those treated with the standard antifungal drug Miconazole [half of the total patients] did the same in the longer period of 3-8 weeks. Photographs showing progress of response to BKO treatments are included. BKO has great potential for development as a commercial drug for the treatment of dertmatophytes

A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis.

BACKGROUND: Treatment of tinea pedis with conventional oral antifungal agents produces poor response rates. Itraconazole is a broad-spectrum, orally active antifungal agent with pronounced antimycotic activity. However treatment cost of itraconazole is problematical in developing countries. OBJECTIVES: To study the efficacy of the 1-pulse dosing regimen of two generic products of itraconazole (Itracon and Itra) in comparison with the innovative product (Sporal) for the treatment of tinea pedis. MATERIAL AND METHOD: The study was a double-blind randomized controlled trial. One hundred and thirty-three patients with tinea pedis were treated with Itracon, Itra or Sporal 200 mg twice daily for 1 week. Clinical and mycological examinations were performed at baseline and at the follow-up visits (taking place at 1, 2, 4 and 12 weeks after the medication administration). RESULTS: Fifty-four, sixty-one and eighteen patients were randomized to Sporal, Itracon and Itra treatment group respectively. Mycological cure rate and clinical response rates were not significantly different among the three groups. Moreover there were also no statistically significant differences with regard to relapse rate. During treatment, no serious adverse events were recorded in any groups. CONCLUSION: The present study demonstrated that the efficacy of the original and generic itraconazole is not significantly different in the treatment of tinea pedis by the pulse regimen.

Solución para la epidermofitosis de los pies en integrantes de las Fuerzas Armadas Revolucionarias / A solution for treatment of epidermophytosis affecting members of the Revolutionary Armed Forces

Se presenta un trabajo sobre el uso del aceite de girasol ozonizado (oleozón) en la epidermofitosis de los pies, cuyo objetivo principal fue el de generalizar el uso del oleozón en todos los militares que presentaban dicha afección atendidos en el Hospital Militar "Dr. Carlos J. Finlay" en 1998, procedentes de consulta externa, exámenes médicos de control de salud, comisiones médicas e ingresados. Se trataron 257 pacientes, y se curaron 227 enfermos (88,3 porciento). La respuesta según forma clínica más efectiva fue en la escamosa y macerada. No se presentaron efectos adversos. Se realiza una introducción que especifica las características del oleozón, se hace referencia a sus ventajas económicas y sociales(AU) ,

Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis.

OBJECTIVE: To compare the efficacy of terbinafine cream for 1 week with the efficacy of miconazole cream for 4 weeks in the treatment of tinea pedis. METHOD: Patients who visited our clinic for tinea pedis and who had positive KOH preparation and positive culture for dermatophyte were treated with terbinafine cream for 1 week and placebo for 3 weeks, or with miconazole cream for 4 weeks. Evaluation was done 1, 2, 3, 4 and 10 weeks after the start of the treatment. Mycological cure was defined as presence of a positive KOH preparation and a positive culture before treatment, and negative results for both after treatment. Clinical efficacy was defined as mycological cure and presence of at most a total signs and symptoms score of two. RESULT: Forty-eight patients were studied. Half of them were treated with terbinafine and placebo and the other half with miconazole. Both groups had an equal distribution as to age, sex, race, duration and seriousness of the fungal infection and previous treatment. Mycological cure and clinical efficacy throughout the evaluation were similar in both treatment groups. After 10 weeks, mycological cure was seen in about 52.6 per cent and 55 per cent, and clinical efficacy in about 47 per cent, 45 per cent in terbinafine and miconazole treatment group respectively. CONCLUSION: In the treatment of tinea pedis local application of terbinafine cream for 1 week is as good as treatment with miconazole cream for 4 weeks.

Efficacite et tolerance du fluconzole dans le traitement des dermatomycoses

The aim of the study was to evaluate the efficacy and the safety of fluconazole [Diflucan[']], 150mg/ week, for the treatment of Dermatomycosis. This study was a multicenter open study, and three departments of dermatology were involved. One hundred eight patients with Tinea cruris, Tinea corpons or Tinea pedis were recruited. The efficacy evaluation was based on a clinical and mycological assessment. The clinical success rate was 96.6% Mycological eradication was observed in 90.9% of cases and 80.2% at culture Two to three capsules of Difflucan'] were adminstered to 68.2% patients with Tinea cruris or Tinea corporis. Difflucan'] was well tolerated. Eight adverse events were notified during the study all of these events were moderate and didn't require any patients withdrawal

Tiña de los pies. Estudio multicéntrico para valorar la eficacia y tolerancia de una dosis semanal de fluconazol / Tinea pedi. A multicenter trial to evaluate the efficacy and tolerance of a weekly dose of fluconazole

Estudio multicéntrico abierto, no comparativo, en 49 pacientes, con diagnóstico clínico y micológico de tinea pedis. El tratamiento consistió en una dosis semanal (una cápsula) de 150 mg de fluconazol hasta por seis semanas. La mejoría se observó desde la segunda semana de tratamiento. Al final del estudio el 79.5 por ciento de los pacientes alcanzaron la curación clínica, mientras que la erradicación micológica se obtuvo en el 91.8 por ciento de los casos. La dosis promedio utilizada fue de 4.8 cápsulas. Se concluye que el fluconazol, administrado en este esquema posológico, es eficaz y bien tolerado para el tratamiento de pacientes con tinea pedis

Terbinafina oral en tiña pedis: estudio clínico multicéntrico / Oral terbinafine in tinea pedis: multicentric clinical study

Se presenta la experiencia clínica multicéntrica Uruguay-Chile en el tratamiento de la tiña pedis con terbinafina oral administrada por 2 semanas, con períodos de observación postratamiento a las 4 y 8 semanas de inicio del estudio. Se incluyen 67 pacientes,39 mujeres y 28 hombres, con una edad promedio de 38,9 años, que presentaban el cuadro clínico de tiña pedis (forma interdigital y formas plantares difusas, ya sea uni o bilaterales), el que fue confirmado por la presencia de dermatofitos en el cultivo micológico inicial (79,1 por ciento de los casos trichophyton rubrum). Se evaluaron signos clínicos variados: eritema, descamación, vesiculización, presencia de pústulas, exudación, costras y síntoma prurito. La evaluación micológica se efectuó mediante examen directo y cultivo. Los signos y síntomas clínicos mejoraron durante todo el seguimiento, alcanzando entre 61,2 por ciento al 100 por ciento de mejoría total de estos parámetros a las 8 semanas de seguimiento. Los exámenes micológicos se fueron negativizando progresivamente, alcanzando en la evaluación final a las 8 semanas un 92 por ciento de exámenes directos y un 85 por ciento de cultivos negativos, respectivamente. Recaídas con cultivos micológicos positivos fueron observadas en 2 casos (4,3 por ciento). El medicamento fue, en general, bien tolerado, y los efectos adversos más frecuentes fueron gastrointestinales, presentes en 7 pacientes. No se registraron alteraciones de parámetros bioquímicos de significación. En conclusión, la terbinafina (LAMISIL) se presenta como una nueva medicación antimicótica sistémica de alta eficacia en cortos períodos de tratamiento en variadas formas de tiña pedis

Estudio clínico con Fluconazol oral de 150 mgrs. En el tratamiento de pacientes con tiña corporal/crural y tiña de los pies / Clinic study with oral Fluconazol of 150 mg. In the treatment of patient with tinea corporis/cruris and tinea pedis

Para establecer la eficacia y seguridad del fluconzol a dosis oral de 150 mgrs. en forma semanal en el tratamiento de las tiñas corporal/crutal y tiña de los pies se efectuó un estudio global de 22 pacientes de los cuales 12 presentaron tiña corporal/crutal y 10 pacientes tiña de los pies, todos fueron valorados desde el punto de vista tanto clínico y micológico. Durante el mismo se logró una curación clínica y micológica en 18 casos (82 por ciento) del total de pacientes, falla terapéutica en 3 casos (14 por ciento) y reactivación en 1 caso (4 por ciento). La tolerancia como los resultados fueron buenos.

Tratamiento de las dermatomicosis con itraconazol / Treatment of the dermatomycosis with itraconazole

Se presentan los resultados obtenidos con la administración de 100 mg. diarios de itraconazol por vía oral, en 20 pacientes con dermatomicosis. La duración del tratamiento fue de 30 días para tinea manuum-pedis y 15 días para las otras localizaciones de las micosis. No se comprobaron efectos colaterales ni signos de toxicidad atribuibles a la administración del medicamento. Se obtuvo en todos los casos la negativización de los cultivos al finalizar la terapéutica con desaparición de los síntomas y signos de enfermedad.

Estudo multicentrico com tioconazol no tratamento da tinea corporis, cruris ou pedis / Multicenter study with tioconazole in the treatment of tinea corporis, cruris or pedis

Foi realizado um estudo multicêntrico, aberto, näo comparativo em 10 centros universitários de dermatologia no Brasil com a participaçäo de 137 pacientes, utilizando-se um novo derivado imidazólico com potente açäo fungicida - o tioconazol - no tratamento de tinea corporis, cruris ou pedis. Dos 137 pacientes tratados, 44 (32%) eram portadores de T. corporis, 44 (32%) de T. cruris e 49 (36%) de T. pedis. O agente etiológico predominante foi o T. rubrum, responsável por 68 (50%) dos casos, o T. mentagrophytes foi detectado em 32 (23%), o E. floccosum em 25 (18%) e o M. canis em 12 (9%) dos pacientes. O tioconazol foi usado sob a forma de loçäo a 1% e aplicado duas vezes ao dia, durante 4 semanas. Os pacientes foram avaliados clínica e micologicamente no pré-tratamento, na 2ª, 4ª e, se possível, na 8ª semana. A avaliaçäo clínica global ao término do tratamento (4ª semana) evidenciou resultados excelentes ou bons em 132 (96%) pacientes, sendo que nesta ocasiäo 133 (97%) apresentaram cura micológica. Dos 57 paciente que retornaram 4 semanas após o término da terapêutica (8ª semana), em todos constatou-se persistência da cura clínica e micológica. A tolerabilidade ao tioconazol foi excelente, uma vez que somente 2 (1,5%) pacientes apresentaram reaçöes adversas, sendo que destes, em apenas 1 houve necessidade de interrupçäo do tratamento. Em conclusäo, o tioconazol mostrou ser eficaz e seguro no tratamento da tinea corporis, cruris ou pedis